Mode
Text Size
Log in / Sign up
N/A N=62 Randomized Single-blind Supportive Care

User Preference/Validation Evaluation of the New Philips Respironics Positive Airway Pressure Application

Sleep Disordered Breathing

Enrolled (actual)
62
Serious AEs
1.6%
Results posted
Mar 2021
Primary outcome: Primary: User Preference of the New Philips Respironics Positive Airway Pressure Application as Measured by the Attitudes Toward Use Questionnaire — 7.5; 7.9; 8.8 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Standard of Care (Other); DreamMapper Application (Device); DreamMapper Application with Therapist Assist (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Philips Respironics
Primary completion
May 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
User Preference of the New Philips Respironics Positive Airway Pressure Application as Measured by the Attitudes Toward Use Questionnaire
7.5; 7.9; 8.8
SECONDARY
Adherence
4.6; 4.8; 4.0
SECONDARY
Treatment Outcomes - Epworth Sleepiness Scale
6.4; 7.9; 7.7
SECONDARY
Treatment Outcomes - Functional Outcomes of Sleep Questionnaire (FOSQ)
15.9; 16.0; 17.6
SECONDARY
Site Economic Savings Assessed by Number of Phone Calls.
6; 7; 9
SECONDARY
Patient Interactions
2; 3; 4
SECONDARY
Mask Refits
2; 2; 3
SECONDARY
Overall Economic Cost Saving

Summary

This pilot study is intended to evaluate the acceptance and performance of the DreamMapper application and the Therapist Assist educational tool in naïve patients with Obstructive Sleep Apnea who have been prescribed Positive Airway Pressure therapy. A total of approximately 60 naïve participants will be recruited.

Eligibility Criteria

Inclusion Criteria

  • Age 21-75
  • Diagnosis of Obstructive Sleep Apnea (OSA) with an Apnea Hypopnea Index (AHI) of at least 15 events/hour of sleep and a Central Apnea Index (CAI) ≤ 5 events /hour or ≤ 50% of the AHI.
  • Newly diagnosed and Continuous Positive Airway Pressure (CPAP) Naïve.
  • Currently owns and uses apps on an Android or iPhone smart phone.
  • Willing to undergo an attended in lab Polysomnography (PSG)
  • Willing and able to provide informed consent.
  • Speaks and reads English as their primary language.

Exclusion Criteria

  • Presence of poorly managed or unstable major medical or psychiatric conditions that would interfere with the demands of the study, adherence to positive airway pressure, or the ability to complete the study. For example, unstable congestive heart failure, chronic lung disease with daytime hypercapnia, neuromuscular disease, psychiatric disease, cancer, or chronic renal failure.
  • Participants who are unwilling to try Positive Airway Pressure (PAP) therapy.
  • Participants currently prescribed oxygen therapy (as needed, nocturnal, or continuous).
  • Participants with previously diagnosed respiratory failure or respiratory insufficiency.
  • Recent surgery of the upper airway, noise, sinus, or eyes.
  • Participant is prescribed a BiPAP device
  • Commercial Drivers
  • Shift workers
  • Participants with untreated periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index > 15).
  • Participants with untreated known diagnosis of Insomnia (score of 15-21(moderate severity) per Insomnia Severity Index (ISI) )
  • Known diagnosis of bipolar disorder
  • Participant with unstable anti- depressant medication (not stable for 3 months)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03748264). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search